Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vildagliptin Oral Antidiabetic Agent – For The Treatment of Type 2 Diabetes

Drug (Brand / Generic)

Galvus (vildagliptin)

Company / Licensee

Novartis

Therapy Class

DPP-IV inhibitor

Product Description

Inhibits action of DPP-IV, so delaying degradation of GLP-1

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved Europe; pre-registration US
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top